Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06878235
Active, not recruiting Observational

Validation of the French Version of the Primary Lateral Sclerosis Functioning Rating Scale (PLSFRS)

NCT06878235 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Tours
Phase
Observational
Started
2025-04-11
Last updated
2026-05-06

Condition(s) studied

Lateral Sclerosis

Investigational drug(s) / intervention(s)

Assessment of the functional status

Assessment of the functional status: assessment of their functional status using the French version of the PLSFRS scale during a routine multidisciplinary assessment every 3-6 months for all patients with motor neurone disease, as recommended by the FILSLAN network

Study summary

This is a national, multicentric, prospective, descriptive study evaluating the psychometric properties of the French version PLSFRS scale

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with primary lateral sclerosis (PLS) * Age over 18 years * Informed consent signed * Patients cared in a French ALS centre Exclusion Criteria: * patients with no oral and written command of the French language * Patients unable to answer a questionnaire * Opposition to data processing

Primary outcome measure(s)

  • French version of the PLSFRS scale — inclusion and 6 months
    10 items with a score from 0 to 6; 2 items with a score from 0 to 4 Maximal score is 68.

Trial sites (7)

FacilityCityRegionStatus
University hospital Brest France
University hospital Clermont-Ferrand France
University hospital Lille France
University hospital Limoges France
University hospital Lyon France
University Hospital Nice France
University hospital Tours France

More University Hospital, Tours trials in France

Communication Enhancement Among Ventilated Patients in Intensive Care Recruiting
Social Information Processing in Children: an ocUlo-pupillometric Tool for Standard Evaluation Recruiting
Assessment and Follow-up of Surgical Treatment of Hemivertebra in Children Recruiting
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea Recruiting
Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06878235 on ClinicalTrials.gov ↗ ← All trials in France